Integra LifeSciences (NASDAQ:IART – Get Free Report) is one of 510 publicly-traded companies in the “Healthcare Equipment & Supplies” industry, but how does it compare to its competitors? We will compare Integra LifeSciences to similar businesses based on the strength of its earnings, risk, institutional ownership, analyst recommendations, profitability, dividends and valuation.
Profitability
This table compares Integra LifeSciences and its competitors’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Integra LifeSciences | 0.79% | 18.63% | 5.49% |
| Integra LifeSciences Competitors | -191.42% | -197.84% | -21.82% |
Analyst Recommendations
This is a breakdown of current ratings and price targets for Integra LifeSciences and its competitors, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Integra LifeSciences | 3 | 5 | 2 | 0 | 1.90 |
| Integra LifeSciences Competitors | 4323 | 10552 | 18353 | 839 | 2.46 |
Integra LifeSciences currently has a consensus price target of $16.12, indicating a potential upside of 17.14%. As a group, “Healthcare Equipment & Supplies” companies have a potential upside of 26.81%. Given Integra LifeSciences’ competitors stronger consensus rating and higher probable upside, analysts clearly believe Integra LifeSciences has less favorable growth aspects than its competitors.
Insider & Institutional Ownership
84.8% of Integra LifeSciences shares are held by institutional investors. Comparatively, 40.3% of shares of all “Healthcare Equipment & Supplies” companies are held by institutional investors. 3.8% of Integra LifeSciences shares are held by company insiders. Comparatively, 14.9% of shares of all “Healthcare Equipment & Supplies” companies are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Risk and Volatility
Integra LifeSciences has a beta of 1.28, indicating that its share price is 28% more volatile than the S&P 500. Comparatively, Integra LifeSciences’ competitors have a beta of 2.53, indicating that their average share price is 153% more volatile than the S&P 500.
Earnings and Valuation
This table compares Integra LifeSciences and its competitors revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Net Income | Price/Earnings Ratio | |
| Integra LifeSciences | $1.64 billion | -$516.47 million | 80.98 |
| Integra LifeSciences Competitors | $1.90 billion | $138.28 million | 5.88 |
Integra LifeSciences’ competitors have higher revenue and earnings than Integra LifeSciences. Integra LifeSciences is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.
Summary
Integra LifeSciences competitors beat Integra LifeSciences on 8 of the 13 factors compared.
About Integra LifeSciences
Integra LifeSciences is a medical technology company that develops products for neurosurgery, surgical care and tissue repair. Its offerings include devices and instruments used in cranial surgery, neuromonitoring and wound reconstruction, as well as materials designed to support the repair or regeneration of tissue. The company’s product portfolio includes dural repair products, cranial stabilization systems, surgical instruments and dermal regeneration products. Integra serves hospitals, surgeons and other healthcare providers in the United States and international markets.
Receive News & Ratings for Integra LifeSciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Integra LifeSciences and related companies with MarketBeat.com's FREE daily email newsletter.
